Education
About Us
Working with TipRanks
Follow Us
Alkermes (ALKS)
NASDAQ:ALKS
ALKS Stock Chart & Stats
$28.61
-$0.20(-0.70%)
At close: 4:00 PM EST
$28.61
-$0.20(-0.70%)
Day’s Range― - ―
52-Week Range$25.17 - $36.45
Previous CloseN/A
Volume176.14K
Average Volume (3M)2.91M
Market Cap
$4.72B
Enterprise Value$4.02B
Total Cash (Recent Filing)$616.45M
Total Debt (Recent Filing)$71.60M
Price to Earnings (P/E)14.2
Beta0.67
Next Earnings
Feb 12, 2026EPS Estimate
0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.68
Shares Outstanding165,117,510
10 Day Avg. Volume3,247,270
30 Day Avg. Volume2,906,563
Financial Highlights & Ratios
PEG Ratio3.47
Price to Book (P/B)3.25
Price to Sales (P/S)3.05
P/FCF Ratio11.73
Enterprise Value/Market Cap0.85
Enterprise Value/Revenue2.64
Enterprise Value/Gross Profit3.07
Enterprise Value/Ebitda9.22
Forecast
1Y Price Target
$44.50Price Target Upside55.54% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering16
EPS Forecast (FY)1.69
Revenue Forecast (FY)$1.47B
Bulls Say, Bears Say
Bulls Say
Financial PreparednessAlkermes plans to fund the acquisition with existing cash and an increased loan facility, indicating financial preparedness.
Market LeadershipAlkermes now appears positioned to be first-to-market with an orexin-2 in both NT1 and NT2, which offers commercial value.
Strategic AcquisitionALKS is doubling down in the sleep space with the acquisition of Avadel, a strategic move that gives ALKS first-mover advantage over Takeda.
Bears Say
Competitive DifferentiationThe effect size was comparable to existing drugs, but it fell below the bar for clear differentiation.
Data Comparability IssuesConcerns arise due to differences in sample size and treatment duration affecting direct comparability of datasets.
Market Impact ConcernsThere is some controversy among sleep specialists about the utility of Lumryz in IH patients, affecting its potential market impact.
Alkermes News
ALKS FAQ
What was Alkermes’s price range in the past 12 months?
Alkermes lowest stock price was $25.16 and its highest was $36.45 in the past 12 months.
What is Alkermes’s market cap?
Alkermes’s market cap is $4.72B.
When is Alkermes’s upcoming earnings report date?
Alkermes’s upcoming earnings report date is Feb 12, 2026 which is in 80 days.
How were Alkermes’s earnings last quarter?
Alkermes released its earnings results on Oct 28, 2025. The company reported $0.684 earnings per share for the quarter, beating the consensus estimate of $0.369 by $0.315.
Is Alkermes overvalued?
According to Wall Street analysts Alkermes’s price is currently Undervalued.
Does Alkermes pay dividends?
Alkermes does not currently pay dividends.
What is Alkermes’s EPS estimate?
Alkermes’s EPS estimate is 0.42.
How many shares outstanding does Alkermes have?
Alkermes has 165,117,510 shares outstanding.
What happened to Alkermes’s price movement after its last earnings report?
Alkermes reported an EPS of $0.684 in its last earnings report, beating expectations of $0.369. Following the earnings report the stock price went up 4.307%.
Which hedge fund is a major shareholder of Alkermes?
Currently, no hedge funds are holding shares in ALKS
Alkermes Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$44.50 (55.54% Upside)
$44.50 (55.54% Upside)
Blogger Sentiment
Bullish
ALKS Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 886.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 5.0%
Last 30 Days ▲ 17.8%
Last 30 Days ▲ 17.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
3.28%
12-Months-Change
Fundamentals
Return on Equity
22.35%
Trailing 12-Months
Asset Growth
8.08%
Trailing 12-Months
Company Description
Alkermes
Alkermes plc is a biopharmaceutical company that focuses on developing innovative medicines to address unmet medical needs in the areas of addiction, schizophrenia, and multiple sclerosis. With a robust pipeline of products, Alkermes leverages its expertise in drug development and formulation technologies to create therapies that improve patient outcomes. The company's core products include Vivitrol, a treatment for alcohol dependence and opioid dependence, and Aristada, an injectable antipsychotic for schizophrenia.
ALKS Company Deck
ALKS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call indicates a strong performance in Q3 2025, with significant revenue growth and raised financial guidance for the year. The acquisition of Avadel Pharmaceuticals is positioned as a strategic move to enhance Alkermes' portfolio and market position. While there are concerns over increased R&D and SG&A expenses, the overall outlook remains positive with promising advancements in the orexin 2 receptor agonist portfolio.View all ALKS earnings summariesALKS Revenue Breakdown
89.69% U.S.
10.24% Rest of world
0.07% Ireland
ALKS Stock 12 Month Forecast
Average Price Target
$44.50
▲(55.54% Upside)
Technical Analysis
Ownership Overview
1.40% Insiders
29.56% Mutual Funds
25.70% Other Institutional Investors
12.43% Public Companies and
Individual Investors